晚期尿路上皮癌可靶向基因变异图谱:高 prevalence 但临床应用有限
该研究对233例MIBC/mUC患者(MIER队列)行靶向测序,发现95%携带至少一种致病/可能致病变异,11%有FGFR3可靶向变异;在40例MTB队列中55%获推荐(5%标签内、50%标签外),但仅1例实际接受治疗。结论:可靶向变异常见,但MTB推荐落地存在显著差距。
要点
- 95%的MIBC/mUC患者携带至少一种致病/可能致病变异。
- 11%患者存在FGFR3可靶向变异,40%有FDA批准疗法的生物标志物变异。
- MTB推荐中仅1例实施,提示治疗可及性与依从性不足。
核心结论
- 多数MIBC/mUC患者存在标签内或标签外治疗的循证指征。
- 可靶向变异高检出与MTB指导治疗的实际实施之间存在显著差距。
研究设计与样本
- 回顾性队列研究,MIER队列233例MIBC/mUC患者接受靶向测序。
- 验证队列为40例常规诊断中接受MTB评估的MIBC/mUC患者。
主要发现
- MIER队列中95%(226/233;95%CI 94-99)携带至少一种致病/可能致病变异。
- FGFR3可靶向变异见于11%(26/233;95%CI 7.4-16)患者。
- 40%(95%CI 34-47)患者在24个FDA批准疗法的生物标志物中检出变异。
- MTB队列中55%获治疗推荐(标签内5.0%,标签外50%),仅1例实施并获4个月疾病稳定(标签外alpelisib)。
- 回顾性分析显示MIER队列中10%和70%可分别适用标签内和标签外指征。
关键数值与推荐
- FGFR3变异检出率11%(26/233;95%CI 7.4-16)。
- 至少一种致病/可能致病变异检出率95%(226/233;95%CI 94-99)。
临床怎么用
- 对MIBC/mUC患者应常规行分子谱检测以识别可靶向变异。
- MTB推荐需加强治疗可及性和医生依从性以缩小实施差距。
局限性
- MIER队列为回顾性设计。
- MTB验证队列样本量仅40例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The Food and Drug Administration and the European Medicine Agency approved erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma (mUC), highlighting the central role of tumor molecular profiling for patients with mUC. Although different studies described the molecular landscape of muscle-invasive bladder cancer (MIBC) using publicly-available data, a dedicated evaluation of real-world actionable alterations, with evidence-based therapeutic recommendations according to current Molecular Tumor Board (MTB) guidelines, is still lacking. DESIGN, SETTING, AND PARTICIPANTS: We characterized actionable genetic alterations in a retrospective cohort of 233 patients with MIBC/mUC (Muscle-Invasive Erlangen [MIER] cohort) using targeted sequencing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinically relevant variants were assessed through a custom bioinformatics workflow and expert medical review. To validate their clinical relevance in a real-world setting, we examined actionable alterations and associated therapy recommendations in a cohort of 40 patients with MIBC/mUC undergoing routine diagnostics (MTB cohort). RESULTS AND LIMITATIONS: In the MIER cohort, 95% of patients (n = 226/233; 95% confidence interval [CI], 94-99) harbored at least one pathogenic/likely pathogenic variant. Therapeutically relevant FGFR3 alterations were identified in 11% of patients (n = 26/233; 95% CI, 7.4-16). Additionally, 40% of patients (95% CI, 34-47) showed alterations in 24 biomarkers for FDA-approved therapies. In the MTB cohort, 55% of patients received either on-label (5.0%) or off-label (50%) therapy recommendations. Notably, the recommendation was implemented in only one patient, who achieved stable disease for 4 mo with off-label alpelisib. Retrospectively, similar on-label and off-label indications could have applied to 10% and 70% of patients in the MIER cohort, respectively. CONCLUSIONS: Overall, evidence-based indications for on-label and off-label therapies were observed for the majority of patients with MIBC/mUC. However, our results also revealed a significant gap between the high prevalence of actionable findings and the actual implementation of MTB-guided treatments in clinical practice, suggesting a need for enhanced therapy access and physician adherence to MTB recommendations.
引用
- Carta MG, Tögel L, Angeloni M, et al. Landscape of Actionable Genetic Alterations in Advanced Urothelial Carcinoma: High Prevalence but Limited Clinical Use. Eur Urol Oncol. 2026. PMID: 42674932. doi:10.1016/j.euo.2026.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。